BioResearchAI

What BioResearchAI does

BioResearchAI.Co.,Ltd. is a Seoul-based SaaS company that operates the Bio-Research.AI Platform, an AI-powered business development and investment intelligence service for biopharma innovators. The platform aggregates and processes a proprietary database spanning pharmaceutical deals (30K+), VC funding rounds (20K+), drug pipelines (113K+), regulatory guidelines (9K+), and clinical trials (777K+), with a particular emphasis on multilingual primary sources and access to original deal contracts that are not typically available from English-only incumbents such as Citeline or EvaluatePharma.

The product is delivered as a single web-based platform rather than a modular suite, with core capabilities including real-time monitoring and alerting, competitive landscape visualization, deal contract exploration, clinical data comparison across countries, and presentation-ready figure generation. Underlying AI capabilities cover knowledge retrieval across global registries, natural language processing for multilingual guideline comparison and automated news writing, real-time anomaly detection for data integrity, and process automation for continuous monitoring. Access is via self-serve sign-up with Google or LinkedIn OAuth and a free trial.

The business model is annual SaaS subscription priced at approximately $5.9K, positioned as 20x cost efficient versus traditional pharma intelligence services priced around $100K. Target customers are enterprise pharmaceutical companies (especially business development teams) and venture capital firms investing in early-stage biotech. Distribution is product-led and digital-first via the bio-research.ai website, with no disclosed channel partnerships. The company was founded in June 2022 by Jason Lee (CEO) and as of April 2024 had raised a cumulative 3 billion won (approximately $2.2M USD) including a Pre-A round from BSK Investment, Heungkuk Asset Management, KAIST Venture Investment Holdings, and Shinhan Capital.

Name

BioResearchAI

Legal name

BioResearchAI.Co.,Ltd.

Website

https://bio-research.ai

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

BioResearchAI is a Seoul-based SaaS platform providing AI-powered pharmaceutical and biotech intelligence, including deal tracking, pipeline analysis, and clinical data comparison, to enterprise biopharma business development teams and biotech-focused venture capital firms.

Ownership category

akta.pro rank

Product category

Pharmaceutical and Biotech Intelligence Software

NAICS

Software Publishers (513210), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Pharmaceutical intelligence
• Biotech data analytics
• Clinical trial tracking
• Drug pipeline analysis
• Regulatory guideline database

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. SaaS Subscription Platform Access: Annual or monthly subscription providing access to the BioResearchAI intelligence platform covering deals, funding, pipelines, regulatory guidelines, clinical trials, and original contracts. The platform is priced at approximately $5.9K according to marketing claims about delivering $100K worth of insights.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BioResearchAI operates an AI-powered SaaS intelligence platform for biopharma innovators that aggregates deals, VC funding, drug pipelines, regulatory guidelines, clinical trials, and original contracts in one workspace. The platform enables competitive landscape analysis, deal tracking, clinical data comparison, multilingual guideline review, and real-time alerting, all delivered via a self-serve web application that customers can trial via Google or LinkedIn sign-up.

Product overview

BioResearch.AI is a single unified platform (not modular) providing AI-powered business development and investment intelligence for biopharma innovators. The core Bio-Research.AI Platform serves as the central offering, delivering real-time BD and investment data, competitive landscape visualization, AI-tracked updates, deal contract exploration, and multilingual guideline comparison—all accessible through a web-based interface. The platform covers 30K+ deals, 20K+ VC funding rounds, 113K+ pipelines, 9K+ regulatory guidelines, and 777K+ clinical trials across license agreements, M&A, R&D collaborations, and other deal types. Pricing is approximately $5.9K (positioned as 20x cost efficiency versus traditional $100K analyst insights), with data sourced including financial terms, rights, deal history, drug profiles, clinical updates, regulatory information, and original contracts.

Differentiator

Problem solved

Functional benefit

Products and services

• Bio-Research.AI Platform Self-serve SaaS platform that delivers AI-powered business development and investment intelligence for biopharma innovators, providing real-time monitoring, competitive landscape analysis, deal tracking, clinical data comparison, multilingual regulatory guideline review, and access to original deal contracts covering drug profiles, funding, pipelines, clinical trials, and patent data.

Quantifiable outcome

• 20x cost reduction: $5.9K price providing $100K equivalent insights
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature6 records

Scale indicators3 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• AlphaSense: AlphaSense is an AI-powered market and competitive intelligence platform serving enterprises with NLP-driven document search — comparable in technology (AI/NLP over large corpora), GTM (PLG/self-serve) and target buyer (enterprise strategy/BD teams) to BioResearchAI, though broader in vertical scope.
• DealForma: DealForma is a biopharma deal intelligence database tracking licensing, M&A and financing transactions — directly competing with BioResearchAI's deal-tracking and contract-exploration features and serving the same BD audience.
• Evaluate Pharma (Norstella): Evaluate Pharma provides pharma deal, pipeline and forecast intelligence used by BD and investment teams — closely overlapping in product (deals, pipelines, forecasts) with BioResearchAI, and is one of the primary $100K-tier incumbents BioResearchAI targets at a fraction of the price.
• CB Insights: CB Insights provides AI-driven market intelligence on tech, healthcare and biotech including deal tracking, funding data and trend analysis — a closely analogous AI-intelligence SaaS model targeting VC and corporate strategy buyers, overlapping with BioResearchAI's VC pharma analytics use case.

Broad incumbents

• PitchBook (Morningstar): PitchBook provides deal, VC funding and private-company intelligence used by biotech VCs and corporate BD — closely overlapping with BioResearchAI's VC-facing funding-tracking and deal-sourcing features, though broader in vertical scope.
• IQVIA (formerly IMS Health): IQVIA is the largest global life-sciences data and analytics provider, spanning clinical, commercial and real-world data — competes most directly with the enterprise-pharma analytics layer BioResearchAI targets, and represents the dominant $100K+ alternative buyer will benchmark against.
• GlobalData Healthcare: GlobalData's healthcare vertical provides pharma pipeline, clinical trial, deals and regulatory intelligence comparable in scope to BioResearchAI; as a broader data-and-analytics incumbent it represents the same $100K-tier alternative BioResearchAI is undercutting.
• Cortellis (Clarivate): Cortellis by Clarivate provides drug pipeline, clinical trial, patent and regulatory intelligence for pharma R&D and BD teams — overlapping with BioResearchAI's pipelines/clinical/regulatory/patent dataset as an enterprise incumbent offering.
• Citeline (Pharma Intelligence): Citeline (formerly Informa Pharma Intelligence) offers clinical trial intelligence, deal tracking and pipeline analytics for pharma BD/investment professionals — directly comparable content scope to BioResearchAI, but with much higher pricing, broader coverage and an enterprise sales motion.

Emerging players

• Pharmcube (Yaozhi): Pharmcube (Yaozhi) is a Chinese-language pharma intelligence platform aggregating drug, clinical, regulatory and deal data for Chinese pharma BD teams — comparable data scope and emerging-market intelligence positioning to BioResearchAI's multilingual Asia play.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioResearchAI